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Rheumatoid arthritis, currently regarded as a complex
multifactorial disease, was initially characterized as
such at the turn of the 19th century. Ever since,
multiple lines of investigation have attempted to
elucidate the etiological factor(s) involved in disease
incidence. Genes – including those risk alleles within
HLA-DR4 – have been implicated but are insufficient
to explain the vast majority of cases. Several
environmental factors, therefore, are being studied.
Among them, the role of periodontal disease and
Porphyromonas gingivalis in the pathogenesis of
rheumatoid arthritis has attracted both clinical and
bench interest given supportive epidemiologic and
mechanistic data.logic changes at the very onset of disease [2,3]. TooThe notion that rheumatoid arthritis (RA) is a polygenic
autoimmune disorder that requires environmental fac-
tors in order to become clinically apparent is not novel.
Since the very beginning, infectious agents have been
implicated. This includes early theories such as the ‘oral
sepsis’ hypothesis, which supported the notion that
periodontal infections were the true etiologic factors
behind many chronic diseases. Soon after, dental extrac-
tion became a central part of the RA therapeutic
armamentarium.
Over the last decade, an ever-increasing body of litera-
ture has been devoted to study the association between
periodontal disease, Porphyromonas gingivalis, and RA. In
this issue of Arthritis Research & Therapy, Arvikar and
colleagues [1] demonstrate a positive correlation between
P. ginigivalis antibody responses and presence/levels of* Correspondence: jose.scher@nyumc.org
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© BioMed Central Ltd.2013anti-cyclic citrullinated peptide antibodies in a subset of
patients with early RA. Moreover, subjects with serological
reactivity toward P. ginvgivalis also tended to have higher
RA disease activity as measured by Disease Activity Score
in 28 Joints and Clinical Disease Activity Index. This oc-
curred both at baseline – that is, in recently diagnosed pa-
tients who have not previously been treated with disease-
modifying anti-rheumatic drugs (DMARDs) – and 12
months after initiation of therapy.
The study had several strengths. First, the authors en-
rolled early RA patients who were DMARD-naïve at the
time of antibody measurements and clinical assessments.
Second, patients were followed for a period of 1 year to
address biologic and phenotypic alterations after
initiation of therapy. This is of utmost importance since
very few studies have addressed clinical and immuno-
often, however, the natural history of RA is studied with-
out considering the confounding effects of long-standing
systemic inflammation or immunosuppressive therapies
or both. It is almost certain that the use of DMARDs
and biologics alters the quantification and behavior of
multiple immune cells and proteins (including auto- and
alloantibody responses), thus distorting the true under-
standing of disease pathogenesis. Efforts to elucidate the
earliest changes in pre-clinical and clinical RA are un-
derway [2,4].
An accumulating body of evidence suggests a role
for clinical periodontal diseases in RA pathogenesis.
Periodontitis was more common and severe in patients
with RA compared with osteoarthritis [5], and subjects
with RA had an increased likelihood of periodontitis
compared with controls [6]. Multiple recent studies have
specifically implicated P. gingivalis, a periodontopathic
bacterium, as a possible triggering factor. This micro-
organism has gained scientific attention given its ability
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conferred by peptydil arginine deiminase (PAD), which
reportedly promotes the generation of neoantigens and
the subsequent production of antibodies to citrullinated
protein antigens (ACPAs). Experimentally, P. gingivalis-
PAD is capable of citrullinating human peptides [7] and
ACPAs have proven pathogenic in murine models of
arthritis [8].
A decade ago, it was postulated that a specific humoral
immune response to P. gingivalis was the actual stimulus
for the development of RA [9]. Since then, multiple re-
ports used serological methods [10,11] to correlate the
generation of antibodies to P. gingivalis with auto-
immunity (that is, ACPA antibodies) and clinical RA.
Several lessons can be learned from these types of ap-
proaches. First, as in the case of reports by Arvikar and
colleagues [1] and others [2,10,11], the methodology and
antigens used to quantify anti-P. gingivalis antibodies
have been heterogeneous. Prior studies used antibodies
against whole-cell, bacterial lipopolysaccharide, or P.
gingivalis-specific chaperone protein. The sensitivity and
specificity of each one of these antibodies (and their
measurements through different phases of disease) add
to the complexity of correlating P. gingivalis serologic
responses to RA pathogenesis. A concerted effort toward
standardization is warranted in the interest of scientific
validation and replication. Second, very few studies have
reported the direct presence of P. gingivalis (or other
periodontopathic bacteria) in subgingival biofilms of pa-
tients with RA. This can now be achieved without the
need for laborious, classic microbiologic culture tech-
niques. The advent of high-throughput, bacterial DNA
sequencing has allowed taxonomic classification of mul-
tiple bacterial species within hundreds of samples (that
is, microbiome analysis) in a matter of days.
Finally, and perhaps more importantly, virtually all
studies consistently reported only a small fraction of RA
patients as being exposed to P. gingivalis (serologically,
microbiologically, or both). This can have several (and
possibly complementary) explanations. It is conceivable
that the overabundance of other, non-measured,
periodontopathic bacteria (or the lack of protective flora
or both) contributes to disease initiation. Moreover, ex-
posure to bacterial antigenic burden at other body sites,
such as the lung or the gut, may represent triggering fac-
tors for RA. The intestinal microbiome, for example, is
vast and diverse. It contains 100 times more protein-
coding genes than the human genome and harbors 100
trillion cells (10-fold the amount of total host human
cells). Studies in animal models support the notion that
the oral, lung, or intestinal microbiome (or a combin-
ation thereof ) is required to develop inflammatory arth-
ritis. This is based on the fact that rodents do not
develop joint inflammation under germ-free conditionsor when treated with antibiotics. It is plausible, there-
fore, that an alteration in the bacterial taxa of several
mucosal sites (including oral, lung, and intestinal
microbiomes) is required for the transition from a pre-
clinical, autoimmune phase of RA into clinically classifi-
able disease.
Novel and comprehensive approaches for the study of
the microbiome and the initiation of RA are now pos-
sible. Immunologic and microbiome analyses in pro-
spective cohorts of subjects with periodontal disease and
other risk factors for the development of RA (for ex-
ample, first-degree relatives, discordant twins, or asymp-
tomatic individuals with circulating autoantibodies or a
combination thereof ) may help elucidate some of these
questions and ultimately target these organisms (or their
components) as a diagnostic or even preventive strategy
for RA.
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